The Investor Checklist: What PE Firms, Family Offices, and Entrepreneurs Look for Before They Write the Check

Written by Bill Walker, Founder & CEO, Aesthetic Brokers — Former buy-side M&A executive, DSO platform acquisition lead, and Marine aviator. Bill has represented aesthetic practice founders through the full transaction lifecycle and brings the investor’s perspective to every sell-side engagement.

---

The practices getting the highest multiples right now aren’t always the biggest. They’re the most transferable.

That distinction —between a practice built around an owner and one built to run without them— is the variable investors take into account more than any other. It explains why a $1.5M practice with documented systems can walk away with a higher multiple than a $4M practice where the founder is in the treatment room six days a week. Revenue is the number founders lead with. It is one of the least predictive factors in deal value.

When I was on the buy side evaluating hundreds of P&Ls, the financial analysis was really just the front door. What we were actually asking, every time, was a simpler question: if this owner walks out on Day 31, what happens? The answer to that question sets the multiple —not the top line.

If you’re starting to pay attention to the PE consolidation wave in aesthetics —you’ve received an unsolicited inquiry, heard a peer mention their “walk away number,” or started researching what your practice is actually worth— this is the framework you need before you engage anyone.

---

Why Your Revenue Number Is Almost Irrelevant to Buyers

Here’s what most practice owners don’t understand when they first start thinking about a sale: buyers don’t buy revenue. They buy earnings. Specifically, they buy adjusted EBITDA — your earnings before interest, taxes, depreciation, and amortization, recalculated to reflect what the business actually produces under normalized, post-transaction conditions.

Single-location practices in aesthetics typically transact at 4x–9x adjusted EBITDA. Multi-location platforms reach 7x–13x+, based on available benchmarking data from HealthFMV and Breakwater M&A (2026). Each additional profitable location adds approximately 0.5x–1.0x to the multiple. The gap between those ranges — which can represent $2M–$5M on the same underlying practice — comes down almost entirely to the six criteria below.

The Transferability Test

Underneath every financial model, every letter of intent, every quality of earnings report, investors are asking one thing: does this work without you?

They want to know that if you’re out skiing and you run into a tree and you’re laid up for several months, the practice keeps running. That is not a colorful hypothetical. That is the exact lens through which every structural element of your practice gets evaluated.

This reframe changes everything about how you should think about preparation. It’s not about hitting a revenue milestone before you go to market. It’s about demonstrating that the value you’ve built isn’t locked inside your personal schedule.

---

The Three Buyer Categories in Aesthetics — and What Each One Wants

Not every buyer evaluating your practice is the same. Understanding who is in the room — and what they’re optimizing for — is foundational deal literacy.

Buyer Type	Capital Source	Typical Deal Size	Stay-On Expectations	Primary Focus
Private Equity (Small-/Micro-Cap)	Fund capital	$3M–$30M+ enterprise value	3–5 years (typical)	EBITDA growth, platform scalability, add-on acquisitions
Family Office / Private Wealth Fund	HNW individual or family capital	$2M–$20M+	Flexible	Stable returns, founder alignment, cultural fit
Entrepreneur by Acquisition	SBA loan or private sponsorship	$1M–$5M	Varies	Operational upside, owner-operator transition

Private Equity Firms (Small-Cap / Micro-Cap)

These are the buyers generating most of the activity in the aesthetic consolidation space right now. They are financial professionals who understand healthcare practice economics, and they are building platforms — acquiring a first practice, then adding locations to scale toward a larger exit at a higher multiple.

PE firms are disciplined evaluators. They will run a quality of earnings analysis. They will scrub your finances line by line. They will model your EBITDA forward. And they will weigh your multiple almost entirely on whether the practice can function and grow after you reduce your clinical footprint.

Family Offices and Private Wealth Funds

Family offices tend to bring more flexibility on deal structure and stay-on terms. They’re often less aggressive on post-close operational transformation and more focused on stable, consistent returns. Cultural alignment matters more in these conversations than in pure PE transactions.

The risk here is that without competitive process design, family office conversations can feel friendly and move slowly —which benefits the buyer. Likability is not a signal of fairness.

Entrepreneurs by Acquisition

Post-MBA operators who want to run a business, funded by SBA loans or private sponsors. These buyers are motivated and often move faster than institutional capital. What they prioritize is an operationally sound practice with upside they can capture —meaning they’re evaluating the same transferability criteria as PE buyers, with slightly less institutional discipline behind the analysis.

---

The Investor Checklist: 6 Criteria Evaluated Before Any Offer Is Made

This is what investors are actually looking at. Not the revenue number. These six criteria.

1. Redundant, Replicable Program Processes — Not Magic

Buyers want to see that what happens inside your practice works because of the system, not the person. Documented clinical protocols, repeatable patient journeys, trained staff who execute consistently —this is what “redundant, replicable program processes” means in practice.

You don’t want magic in the kitchen. What comes out should come out the same way every time, regardless of who’s back there.

Practices with documented SOPs, structured treatment menus, and cross-trained providers demonstrate to investors that the value is institutional —not personal. Practices where quality lives entirely in the owner’s hands are structurally unpredictable, and investors price that risk directly into the multiple.

2. Owner Concentration — The #1 Deal-Killer

This one deserves its own section, because it quietly disqualifies more practices than any other single factor.

When the owner personally performs 60% or more of treatments, multiples compress to approximately 3.5x–5.0x adjusted EBITDA, based on available data from Breakwater M&A (2026). Practices where the owner has moved to a management role —overseeing providers but not delivering the majority of treatments— transact in the 7.0x–9.0x range. That gap represents millions in final deal value on the same underlying business.

The reason is straightforward. If you are the practice —if patients come because of you, if revenue stops when you step out of the room— the buyer isn’t acquiring a business. They’re acquiring a dependency. And they’ll price it that way.

Reducing owner concentration is a one-to-three-year process. It requires deliberate delegation, provider development, and patient communication that builds loyalty to the practice brand rather than the individual provider. It can be done. But it doesn’t happen in the six weeks before you engage a buyer.

“They want to know that if you’re out skiing and you run into a tree, the practice keeps running.” — Bill Walker, Aesthetic Brokers

3. Revenue Mix and Modality Diversification

Investors want to see a practice that doesn’t depend on one treatment, one provider, or one revenue source. Overlap across energy-based devices, neuromodulators, prescription services, membership revenue, and skin care builds a more defensible business.

A practice generating 70% of revenue from one device or one provider is a single-point-of-failure operation. Buyers model that risk. A diversified revenue mix signals that the practice can absorb a provider departure, a device issue, or a market shift without a catastrophic revenue event.

4. Clean, Inspectable Financials

Buyers will live inside your P&L. The quality of earnings process isn’t just about verifying revenue —it’s about understanding what’s real, what’s recurring, and what’s owner-specific.

Know your numbers. Know your adjusted EBITDA. Know which expenses are personal (the vehicle on the practice books, the owner health insurance, the phone plan) and which are operational. Those owner-specific add-backs are legitimate and meaningful —but they need to be documented clearly before you sit across from a buyer.

If your financials require significant explanation every time someone looks at them, that’s a problem. Clean, auditable books accelerate diligence and reduce the risk of a re-trade. Messy financials are a buyer’s most effective tool for renegotiating after exclusivity begins.

5. Regulatory Compliance

Compliance issues discovered during diligence can cut deal value materially. In one documented case, an expected $100-per-unit payout dropped to approximately $62 after a compliance finding — a 38% reduction in realized value from a single diligence discovery. Individual outcomes vary significantly; this figure reflects one specific transaction, not a universal benchmark.

Medical aesthetic practices operate in a heavily regulated environment. Scope of practice issues, supervision agreements, medical director arrangements, controlled substance protocols, and state-specific requirements are all areas where gaps get surfaced and repriced into the deal.

Inspect what you expect. If you expect to do well in your practice, you’ve got to know what’s in it.

6. Scalability Signal — Can This Work Without You?

This ties back to the transferability test, but specifically at the platform level. PE buyers are building a platform of 35 or 45 or 55 locations. What they need to know is whether your practice can serve as a foundation for that build, or whether it requires so much owner-specific energy to maintain that adding it creates complexity rather than value.

Ask yourself: if a capable operator took over your day-to-day management tomorrow, what would break? Those are the things that need to be built, documented, or delegated before you go to market.

---

The 3 Structural Problems That Quietly Disqualify Practices

Most founders who approach buyers have no idea their practice has a disqualifying structural issue. These three appear repeatedly.

---

Not sure where your practice lands on this checklist? We offer confidential practice assessments — no obligation, no pressure. Get a confidential practice assessment →

---

The Owner-as-Brand Problem

You’ve spent years becoming the best injector in the room. That’s exactly the problem.

Practices where the owner’s personal reputation is the primary patient retention mechanism are extremely difficult to transfer. Patients come because of you. When a buyer models forward revenue after a transition, they have to assume a percentage of those patients follow you out the door — and they price that assumption into the offer.

The solution isn’t to stop being excellent. It’s to systematically transfer patient loyalty to the practice brand, the team, and the experience — not the individual. A year or two of deliberate attention can shift the valuation tier you’re in.

The Expansion Trap

More space. More staff. More equipment. Same EBITDA — or lower — than seven years ago.

This is the expansion trap, and it’s more common than most founders want to admit. Device financing at high APRs compresses margins. Additional payroll without proportional revenue growth compresses margins. Lease obligations on expanded space compress margins. When margins compress, EBITDA compresses. When EBITDA compresses, deal value compresses — regardless of how impressive the top line looks.

Before adding significant overhead, model the EBITDA impact, not just the revenue opportunity. Buyers pay for margins, not for scale.

The One-Year-Delay Fallacy

“I’ll wait until revenue is a little higher.”

This is the most common objection I hear — and often the most expensive mistake. Waiting another year rarely produces a meaningfully higher multiple, because buyers price forward EBITDA potential, not trailing revenue peaks. That year frequently produces burnout, staff turnover, market saturation, or multiple compression as the consolidation window matures.

The risks of waiting almost always exceed the upside. The founders who close at the strongest multiples are the ones who started preparing 18–24 months before they were ready to sign anything.

---

When Is the Right Time to Sell? Earlier Than Almost Every Owner Thinks

Medical aesthetics is approximately 3%–4% PE-consolidated right now. That sounds like there’s runway. Here’s the framing that changes the math.

This is not $177 billion dentistry. The dental consolidation wave took 25 years. Aesthetics won’t take 25 years. If you think the current level of PE interest in practices is permanent, that’s not a realistic assumption — and it’s an expensive one to act on. The window is real, but it isn’t unlimited.

Being early in the consolidation cycle means something specific: you’re not just getting a premium single exit — you’re potentially accessing compounding multiples. When a platform you’ve joined grows from four locations to forty-five and sells to the next tier of investor, the equity you rolled at close participates in that event. That’s the second bite of the apple. The earlier you join a disciplined platform, the more compounding works in your favor.

Extend your scan out on the horizon so your wings are level. If you can reach your 10-year success story in three or four years, under the right conditions — you should. That’s not rushing. That’s math.

---

How to Start Passing the Investor Checklist Today

You don’t have to be ready to sell to start getting ready.

Three immediate actions move the needle before anything else:

Reduce your personal treatment volume. Start delegating. Cross-train your team. Begin building patient relationships with other providers in the practice. Moving from 70% personal treatment delivery to 45% over 18 months changes the valuation tier you’re in.

Document your SOPs. Clinical protocols, patient journey, onboarding, treatment workflows, staff training — write it down. If it only exists in your head, it doesn’t exist to a buyer.

Clean up your financials. Work with your CPA to normalize your P&L. Identify and document legitimate add-backs. Know your adjusted EBITDA number before anyone else does. If you don’t know it, that’s where to start.

The full preparation timeline for most practices is one to three years. Founders who are most frustrated by M&A processes are usually the ones who waited until they were already burned out. The founders who close at the top of the range started having this conversation long before they needed to.

---

What to Do Next

The investor evaluation framework isn’t complicated — but it requires honest self-assessment against criteria most founders have never been given.

Where does your practice stand today on the six criteria above? Rate yourself. Then ask: what would it take to move from a 4x practice to a 7x practice? That question — and the work behind it — is worth more than any revenue milestone you’re waiting to hit.

The founders who get the best outcomes start having this conversation 18–24 months before they’re ready to sign anything. Not because they need the time to prepare — because they need the time to build what buyers actually buy.

---

Get a Confidential Practice Assessment

We’ll tell you exactly where you stand — and what it would take to command a premium multiple. No obligation. No pressure. This is the conversation that should happen before any buyer conversation starts.

Get a confidential practice assessment →

---

Disclaimer: This article is for informational purposes only and does not constitute financial, legal, or investment advice. Practice valuations and transaction outcomes vary significantly based on individual circumstances. Consult a qualified M&A advisor and legal counsel before making decisions related to the sale of your practice.

---

Frequently Asked Questions